Apimeds Pharmaceuticals US, Inc. - APUS
Detailed investor-level table based on 13F positions.
Early Q4 2025 data: only 7 institutional holders reported so far. The full shareholder list will grow as more funds file with the SEC.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemenway Trust Co LLC | History | New | 250,000 | 445 | 0.03% | — | 1 | +250,000 | New | Q3 2025 | Nov 07, 2025 |
| VANGUARD GROUP INC | History | New | 58,992 | 105 | 0.0% | — | 2 | +58,992 | New | Q3 2025 | Nov 07, 2025 |
| GEODE CAPITAL MANAGEMENT, LLC | History | New | 30,754 | 54 | 0.0% | — | 3 | +30,754 | New | Q3 2025 | Nov 12, 2025 |
| RENAISSANCE TECHNOLOGIES LLC | History | New | 27,893 | 49 | 0.0% | — | 4 | +27,893 | New | Q3 2025 | Nov 13, 2025 |
| XTX Topco Ltd | History | New | 18,735 | 33 | 0.0% | — | 5 | +18,735 | New | Q3 2025 | Nov 14, 2025 |
| HRT FINANCIAL LP | History | New | 13,572 | 24 | 0.0% | — | 6 | +13,572 | New | Q3 2025 | Nov 14, 2025 |
| Yorkville Advisors Global, LP | History | Closed out | 0 | 0 | — | 0.13% | — | -250,000 | -100.0% | Q2 2025 | Nov 21, 2025 |
| CITADEL ADVISORS LLC | History | Closed out | 0 | 0 | — | 0.0% | — | -13,359 | -100.0% | Q2 2025 | Aug 14, 2025 |
| GOLDMAN SACHS GROUP INC | History | Closed out | 0 | 0 | — | 0.0% | — | -11,987 | -100.0% | Q2 2025 | Aug 14, 2025 |
| Tower Research Capital LLC (TRC) | History | Closed out | 0 | 0 | — | 0.0% | — | -3,151 | -100.0% | Q2 2025 | Aug 15, 2025 |
| JPMORGAN CHASE & CO | History | Added to | 8 | 0 | — | — | — | +3 | 60.0% | Q3 2025 | Nov 26, 2025 |
| BANK OF AMERICA CORP /DE/ | History | No change | 29 | 0 | — | — | — | 0 | 0.0% | Q3 2025 | Feb 03, 2026 |